Drug Information
Drug (ID: DG01645) and It's Reported Resistant Information
| Name |
PLX7904
|
||||
|---|---|---|---|---|---|
| Synonyms |
PLX7904; 1393465-84-3; PB04; PLX-7904; 5-(2-Cyclopropylpyrimidin-5-yl)-3-[3-[[ethyl(methyl)sulfamoyl]amino]-2,6-difluorobenzoyl]-1H-pyrrolo[2,3-b]pyridine; N'-(3-{[5-(2-Cyclopropylpyrimidin-5-Yl)-1h-Pyrrolo[2,3-B]pyridin-3-Yl]carbonyl}-2,4-Difluorophenyl)-N-Ethyl-N-Methylsulfuric Diamide; Sulfamide, N'-[3-[[5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-N-ethyl-N-methyl-; CHEMBL4206836; SCHEMBL15667328; BDBM317744; PLX7904(PB04); BCP18248; EX-A2872; s7964; ZINC144822687; CCG-269789; CS-5129; US9624213, Compound P-0240; HY-18997; A901658; Q27456931; ({3-[5-(2-cyclopropylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluorophenyl}sulfamoyl)(ethyl)methylamine; N'-[3-[[5-(2-cyclopropyl-5-pyrimidinyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-N-ethyl-N-methyl-sulfamide
Click to Show/Hide
|
||||
| Structure |
|
||||
| Drug Resistance Disease(s) |
Disease(s) with Clinically Reported Resistance for This Drug
(1 diseases)
[1]
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Drug | |||||
| Formula |
8
|
||||
| IsoSMILES |
CCN(C)S(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CN=C(N=C4)C5CC5)F
|
||||
| InChI |
InChI=1S/C24H22F2N6O3S/c1-3-32(2)36(34,35)31-19-7-6-18(25)20(21(19)26)22(33)17-12-30-24-16(17)8-14(9-29-24)15-10-27-23(28-11-15)13-4-5-13/h6-13,31H,3-5H2,1-2H3,(H,29,30)
|
||||
| InChIKey |
DKNZQPXIIHLUHU-UHFFFAOYSA-N
|
||||
| PubChem CID | |||||
Type(s) of Resistant Mechanism of This Drug
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | |||||||||||||
|
|
|||||||||||||
| Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [2] | ||||||||||||
| Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | ||||||||||||
| Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
|||||||||||
| Wild Type Structure | Method: X-ray diffraction | Resolution: 2.55 Å | |||||||||||
| Mutant Type Structure | Method: X-ray diffraction | Resolution: 3.20 Å | |||||||||||
| Download The Information of Sequence | Download The Structure File | ||||||||||||
-
420
|
M
M
D
D
R
R
G
G
S
S
H
H
H
H
H
H
H
H
H
H
430
|
H
H
G
G
S
S
E
E
D
D
R
R
N
N
R
R
M
M
K
K
440
|
T
T
L
L
G
G
R
R
R
R
D
D
S
S
S
S
D
D
D
D
450
|
W
W
E
E
I
I
P
P
D
D
G
G
Q
Q
I
I
T
T
V
V
460
|
G
G
Q
Q
R
R
I
I
G
G
S
S
G
G
S
S
F
F
G
G
470
|
T
T
V
V
Y
Y
K
K
G
G
K
K
W
W
H
H
G
G
D
D
480
|
V
V
A
A
V
V
K
K
M
M
L
L
N
N
V
V
T
T
A
A
490
|
P
P
T
T
P
P
Q
Q
Q
Q
L
L
Q
Q
A
A
F
F
K
K
500
|
N
N
E
E
V
V
G
G
V
V
L
L
R
R
K
K
T
T
R
R
510
|
H
H
V
V
N
N
I
I
L
L
L
L
F
F
M
M
G
G
Y
Y
520
|
S
S
T
T
K
K
P
P
Q
Q
L
L
A
A
I
I
V
V
T
T
530
|
Q
Q
W
W
C
C
E
E
G
G
S
S
S
S
L
L
Y
Y
H
H
540
|
H
H
L
L
H
H
I
I
I
I
E
E
T
T
K
K
F
F
E
E
550
|
M
M
I
I
K
K
L
L
I
I
D
D
I
I
A
A
R
R
Q
Q
560
|
T
T
A
A
Q
Q
G
G
M
M
D
D
Y
Y
L
L
H
H
A
A
570
|
K
K
S
S
I
I
I
I
H
H
R
R
D
D
L
L
K
K
S
S
580
|
N
N
N
N
I
I
F
F
L
L
H
H
E
E
D
D
L
L
T
T
590
|
V
V
K
K
I
I
G
G
D
D
F
F
G
G
L
L
A
A
T
T
600
|
V
E
K
K
S
S
R
R
W
W
S
S
G
G
S
S
H
H
Q
Q
610
|
F
F
E
E
Q
Q
L
L
S
S
G
G
S
S
I
I
L
L
W
W
620
|
M
M
A
A
P
P
E
E
V
V
I
I
R
R
M
M
Q
Q
D
D
630
|
K
K
N
N
P
P
Y
Y
S
S
F
F
Q
Q
S
S
D
D
V
V
640
|
Y
Y
A
A
F
F
G
G
I
I
V
V
L
L
Y
Y
E
E
L
L
650
|
M
M
T
T
G
G
Q
Q
L
L
P
P
Y
Y
S
S
N
N
I
I
660
|
N
N
N
N
R
R
D
D
Q
Q
I
I
I
I
F
F
M
M
V
V
670
|
G
G
R
R
G
G
Y
Y
L
L
S
S
P
P
D
D
L
L
S
S
680
|
K
K
V
V
R
R
S
S
N
N
C
C
P
P
K
K
A
A
M
M
690
|
K
K
R
R
L
L
M
M
A
A
E
E
C
C
L
L
K
K
K
K
700
|
K
K
R
R
D
D
E
E
R
R
P
P
L
L
F
F
P
P
Q
Q
710
|
I
I
L
L
A
A
S
S
I
I
E
E
L
L
L
L
A
A
R
R
720
|
S
S
L
L
P
P
K
K
I
I
H
H
R
R
|
|||||||||||||
| Experimental Note | Identified from the Human Clinical Data | ||||||||||||
| In Vitro Model | HCT116 cells | Colon | Homo sapiens (Human) | CVCL_0291 | |||||||||
| A375 cells | Skin | Homo sapiens (Human) | CVCL_0132 | ||||||||||
| A431 cells | Skin | Homo sapiens (Human) | CVCL_0037 | ||||||||||
| SkBR3 cells | Breast | Homo sapiens (Human) | CVCL_0033 | ||||||||||
| SkMEL239-C3 cells | Skin | Homo sapiens (Human) | CVCL_6122 | ||||||||||
| SkMEL239 cells | Skin | Homo sapiens (Human) | CVCL_6122 | ||||||||||
| IPC-298 cells | Skin | Homo sapiens (Human) | CVCL_1307 | ||||||||||
| Colo829 cells | Skin | Homo sapiens (Human) | CVCL_1137 | ||||||||||
| B9 cells | N.A. | Mus musculus (Mouse) | CVCL_1952 | ||||||||||
| In Vivo Model | Mouse xenograft model | Mus musculus | |||||||||||
| Experiment for Molecule Alteration |
Western blot analysis; Microarray gene expression analysis; Crystallization and structure determination assay | ||||||||||||
| Experiment for Drug Resistance |
CellTiter-Glo assay; Anchorage-independent growth assay | ||||||||||||
| Drug Resistance Data Categorized by Their Corresponding Mechanisms | ||||
|
|
||||
| Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
| Resistant Disease | Melanoma [ICD-11: 2C30.0] | |||
| Molecule Alteration | Missense mutation | p.G466E (c.1397G>A) |
||
| Experimental Note | Identified from the Human Clinical Data | |||
| In Vitro Model | SW1736 cells | Thyroid | Homo sapiens (Human) | CVCL_3883 |
| 8505C cells | Thyroid | Homo sapiens (Human) | CVCL_1054 | |
| Hth104 cells | Thyroid gland | Homo sapiens (Human) | CVCL_A427 | |
| In Vivo Model | Mouse xenograft model | Mus musculus | ||
| Mechanism Description | The missense mutation p.G466E (c.1397G>A) in gene BRAF cause the resistance of PLX7904 by aberration of the drug's therapeutic target | |||
| Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | |||||||||||||
|
|
|||||||||||||
| Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [2] | ||||||||||||
| Sensitive Disease | Melanoma [ICD-11: 2C30.0] | ||||||||||||
| Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
|||||||||||
| Wild Type Structure | Method: X-ray diffraction | Resolution: 2.55 Å | |||||||||||
| Mutant Type Structure | Method: X-ray diffraction | Resolution: 3.20 Å | |||||||||||
| Download The Information of Sequence | Download The Structure File | ||||||||||||
-
420
|
M
M
D
D
R
R
G
G
S
S
H
H
H
H
H
H
H
H
H
H
430
|
H
H
G
G
S
S
E
E
D
D
R
R
N
N
R
R
M
M
K
K
440
|
T
T
L
L
G
G
R
R
R
R
D
D
S
S
S
S
D
D
D
D
450
|
W
W
E
E
I
I
P
P
D
D
G
G
Q
Q
I
I
T
T
V
V
460
|
G
G
Q
Q
R
R
I
I
G
G
S
S
G
G
S
S
F
F
G
G
470
|
T
T
V
V
Y
Y
K
K
G
G
K
K
W
W
H
H
G
G
D
D
480
|
V
V
A
A
V
V
K
K
M
M
L
L
N
N
V
V
T
T
A
A
490
|
P
P
T
T
P
P
Q
Q
Q
Q
L
L
Q
Q
A
A
F
F
K
K
500
|
N
N
E
E
V
V
G
G
V
V
L
L
R
R
K
K
T
T
R
R
510
|
H
H
V
V
N
N
I
I
L
L
L
L
F
F
M
M
G
G
Y
Y
520
|
S
S
T
T
K
K
P
P
Q
Q
L
L
A
A
I
I
V
V
T
T
530
|
Q
Q
W
W
C
C
E
E
G
G
S
S
S
S
L
L
Y
Y
H
H
540
|
H
H
L
L
H
H
I
I
I
I
E
E
T
T
K
K
F
F
E
E
550
|
M
M
I
I
K
K
L
L
I
I
D
D
I
I
A
A
R
R
Q
Q
560
|
T
T
A
A
Q
Q
G
G
M
M
D
D
Y
Y
L
L
H
H
A
A
570
|
K
K
S
S
I
I
I
I
H
H
R
R
D
D
L
L
K
K
S
S
580
|
N
N
N
N
I
I
F
F
L
L
H
H
E
E
D
D
L
L
T
T
590
|
V
V
K
K
I
I
G
G
D
D
F
F
G
G
L
L
A
A
T
T
600
|
V
E
K
K
S
S
R
R
W
W
S
S
G
G
S
S
H
H
Q
Q
610
|
F
F
E
E
Q
Q
L
L
S
S
G
G
S
S
I
I
L
L
W
W
620
|
M
M
A
A
P
P
E
E
V
V
I
I
R
R
M
M
Q
Q
D
D
630
|
K
K
N
N
P
P
Y
Y
S
S
F
F
Q
Q
S
S
D
D
V
V
640
|
Y
Y
A
A
F
F
G
G
I
I
V
V
L
L
Y
Y
E
E
L
L
650
|
M
M
T
T
G
G
Q
Q
L
L
P
P
Y
Y
S
S
N
N
I
I
660
|
N
N
N
N
R
R
D
D
Q
Q
I
I
I
I
F
F
M
M
V
V
670
|
G
G
R
R
G
G
Y
Y
L
L
S
S
P
P
D
D
L
L
S
S
680
|
K
K
V
V
R
R
S
S
N
N
C
C
P
P
K
K
A
A
M
M
690
|
K
K
R
R
L
L
M
M
A
A
E
E
C
C
L
L
K
K
K
K
700
|
K
K
R
R
D
D
E
E
R
R
P
P
L
L
F
F
P
P
Q
Q
710
|
I
I
L
L
A
A
S
S
I
I
E
E
L
L
L
L
A
A
R
R
720
|
S
S
L
L
P
P
K
K
I
I
H
H
R
R
|
|||||||||||||
| Experimental Note | Identified from the Human Clinical Data | ||||||||||||
| In Vitro Model | HCT116 cells | Colon | Homo sapiens (Human) | CVCL_0291 | |||||||||
| A375 cells | Skin | Homo sapiens (Human) | CVCL_0132 | ||||||||||
| A431 cells | Skin | Homo sapiens (Human) | CVCL_0037 | ||||||||||
| SkBR3 cells | Breast | Homo sapiens (Human) | CVCL_0033 | ||||||||||
| SkMEL239-C3 cells | Skin | Homo sapiens (Human) | CVCL_6122 | ||||||||||
| SkMEL239 cells | Skin | Homo sapiens (Human) | CVCL_6122 | ||||||||||
| IPC-298 cells | Skin | Homo sapiens (Human) | CVCL_1307 | ||||||||||
| Colo829 cells | Skin | Homo sapiens (Human) | CVCL_1137 | ||||||||||
| B9 cells | N.A. | Mus musculus (Mouse) | CVCL_1952 | ||||||||||
| In Vivo Model | Mouse xenograft model | Mus musculus | |||||||||||
| Experiment for Molecule Alteration |
Western blot analysis; Microarray gene expression analysis; Crystallization and structure determination assay | ||||||||||||
| Experiment for Drug Resistance |
CellTiter-Glo assay; Anchorage-independent growth assay | ||||||||||||
| Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | ||||||||||||
| Sensitive Disease | Melanoma [ICD-11: 2C30.0] | ||||||||||||
| Molecule Alteration | Missense mutation | p.V600R (c.1798_1799delGTinsAG) |
|||||||||||
| Experimental Note | Identified from the Human Clinical Data | ||||||||||||
| In Vitro Model | SW1736 cells | Thyroid | Homo sapiens (Human) | CVCL_3883 | |||||||||
| 8505C cells | Thyroid | Homo sapiens (Human) | CVCL_1054 | ||||||||||
| Hth104 cells | Thyroid gland | Homo sapiens (Human) | CVCL_A427 | ||||||||||
| In Vivo Model | Mouse xenograft model | Mus musculus | |||||||||||
| Mechanism Description | The missense mutation p.V600R (c.1798_1799delGTinsAG) in gene BRAF cause the sensitivity of PLX7904 by aberration of the drug's therapeutic target | ||||||||||||
| Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | ||||||||||||
| Sensitive Disease | Melanoma [ICD-11: 2C30.0] | ||||||||||||
| Molecule Alteration | Missense mutation | p.V600D (c.1799_1800delTGinsAC) |
|||||||||||
| Experimental Note | Identified from the Human Clinical Data | ||||||||||||
| In Vitro Model | SW1736 cells | Thyroid | Homo sapiens (Human) | CVCL_3883 | |||||||||
| 8505C cells | Thyroid | Homo sapiens (Human) | CVCL_1054 | ||||||||||
| Hth104 cells | Thyroid gland | Homo sapiens (Human) | CVCL_A427 | ||||||||||
| In Vivo Model | Mouse xenograft model | Mus musculus | |||||||||||
| Mechanism Description | The missense mutation p.V600D (c.1799_1800delTGinsAC) in gene BRAF cause the sensitivity of PLX7904 by aberration of the drug's therapeutic target | ||||||||||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Yu.
